| Name | ANI-7 |
| Description | ANI-7 is an activator of the aryl hydrocarbon receptor (AhR) pathway, inhibiting the growth of various cancer cells and selectively inhibiting the growth of MCF-7 breast cancer cells (GI50: 0.56 μM). |
| In vitro | ANI-7 (2.5 μM; 24 hours; MCF10A and MDA-MB-468 cells) treatment induces significant S-phase and G2 + M-phase cell cycle arrest within 24 hours in MDA-MB-468 cells. ANI-7 (2 μM; 12-24 hours; MDA-MB-468 cells) significantly increases CHK2 content and phosphorylation and induces a significant increase in H2AXɣ, indicating DNA double-strand damage. GI50 values show ANI-7 has a GI50 of 0.38 μM in MCF-7 cells, while values of 3.0-42 μM are seen in lung, colon, ovary, neuronal, glial, prostate, and pancreas cell lines. The A431 vulva cell line shows appreciable growth inhibition (GI50 of 0.51 μM) by ANI-7. ANI-7 potently inhibits T47D, ZR-75-1, MCF-7, SKBR3, and MDA-MB-468 breast cancer cells (GI50 range 0.16-0.38 μM), moderately inhibits BT20 and BT474 cells (GI50 range 1-2 μM), and essentially fails to inhibit MDA-MB-231 and MCF10A cells (GI50 range 17-26 μM). Additionally, ANI-7 maintains its inhibitory effect on drug-resistant cells (MCF-7/VP16: GI50 of 0.21 μM) [1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 45 mg/mL (171.02 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (7.6 mM), Sonication is recommended.
|
| Keywords | Chk2 | ANI-7 | ANI7 | ANI 7 |
| Inhibitors Related | Rabusertib | Diosmin | Prexasertib | PD0166285 | Sudan IV | 2-Mercaptobenzothiazole | Benzyl butyl phthalate | 1-Hydroxypyrene | Skatole | L-Kynurenine | Indole-3-carbinol | Dibenzothiophene |
| Related Compound Libraries | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Breast Cancer Compound Library | Post-Translational Modification Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Cell Cycle Compound Library | Covalent Inhibitor Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library | Transcription Factor-Targeted Compound Library |
United States
